MK-677 (Ibutamoren) vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
MK-677 (Ibutamoren)
Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| MK-677 (Ibutamoren) | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Ibutamoren, Nutrobal, MK677, L-163,191 | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | Research-stage | Research-stage |
| Dosing range | 10mg–50mg mg, once daily oral | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Oral (capsule/liquid) | Intramuscular injection, Subcutaneous injection |
| Key side effects | Water retention, Increased appetite, Elevated fasting glucose (long-term), Fatigue (initial, transient) | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: MK-677 (Ibutamoren) — Oral (capsule/liquid); Triptorelin — Intramuscular injection, Subcutaneous injection.
- Dosing units differ: MK-677 (Ibutamoren) is dosed in mg, Triptorelin in mcg — they operate at different scales.
- Frequency: MK-677 (Ibutamoren) is typically once daily oral; Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
How each works
MK-677 (Ibutamoren)
MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.